CLOV Quote, Financials, Valuation and Earnings

Centene has a net margin of -6.56% compared to Clover Health Investments's net margin of 0.69%. Clover Health Investments's return on equity of -13.55% beat Centene's return on equity of 12.3%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.08%. On the other hand Centene has an analysts' consensus of $79.66 which suggests that it could grow by 24.75%. Given that Clover Health Investments has higher upside potential than Centene, analysts believe Clover Health Investments is more attractive than Centene.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centene has a beta of 0.529, suggesting its less volatile than the S&P 500 by 47.066%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Centene quarterly revenues of $40.8B. Clover Health Investments's net income of -$22.1M is lower than Centene's net income of $283M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Centene's PE ratio is 10.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.21x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of -6.56% compared to Clover Health Investments's net margin of 0.92%. Clover Health Investments's return on equity of -13.55% beat Elevance Health's return on equity of 14.4%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.08%. On the other hand Elevance Health has an analysts' consensus of $507.81 which suggests that it could grow by 15.46%. Given that Clover Health Investments has higher upside potential than Elevance Health, analysts believe Clover Health Investments is more attractive than Elevance Health.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.773, suggesting its less volatile than the S&P 500 by 22.685%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.5% to investors and pays a quarterly dividend of $1.71 per share. Clover Health Investments pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Clover Health Investments quarterly revenues are $337M, which are smaller than Elevance Health quarterly revenues of $45.4B. Clover Health Investments's net income of -$22.1M is lower than Elevance Health's net income of $418M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Elevance Health's PE ratio is 17.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.58x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -6.56% compared to Clover Health Investments's net margin of -6.42%. Clover Health Investments's return on equity of -13.55% beat Oscar Health's return on equity of 2.46%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.08%. On the other hand Oscar Health has an analysts' consensus of $19.36 which suggests that it could grow by 54%. Given that Oscar Health has higher upside potential than Clover Health Investments, analysts believe Oscar Health is more attractive than Clover Health Investments.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Oscar Health quarterly revenues of $2.4B. Clover Health Investments's net income of -$22.1M is higher than Oscar Health's net income of -$153.5M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Oscar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 0.37x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -6.56% compared to Clover Health Investments's net margin of 3.53%. Clover Health Investments's return on equity of -13.55% beat Progyny's return on equity of 11.14%.

Clover Health Investments has a consensus price target of $4.75, signalling upside risk potential of 29.08%. On the other hand Progyny has an analysts' consensus of $26.75 which suggests that it could grow by 19.74%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.328, suggesting its more volatile than the S&P 500 by 32.843%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are larger than Progyny quarterly revenues of $298.4M. Clover Health Investments's net income of -$22.1M is lower than Progyny's net income of $10.5M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Progyny's PE ratio is 39.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.37x versus 1.85x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.